Mostly Markets
Subscribe
Stocks/Health Care/Biotechnology

AbbVieABBV

Biotechnology · North Chicago, Illinois · In the S&P 500
High quality
$294.89+1.41%After hours: $295.30 (+0.14%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 31.0% over 1 year
AbbVie over 1 yearDaily close, $, to 30 Oct 2026
$200$250Nov2026MarMayJulSep$294.89$200$250NovMarJul$294.89
Source: Nasdaq daily closes
Market value$521B
Price to earnings50.8x
Forward P/E19.6x
Dividend yield2.47%
Year to date+29.1%
One year+31.0%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$197.38$294.89

Quality and valuation

How AbbVie compares with other health care stocks. A description, not a recommendation.

AbbVie and 7 biotechnology peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: stronger than mostValuation: in line with its sector

A stronger business than most health care companies, priced about in line with them.

AbbVie trades at 19.6 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +10.4% vs +7.8%
  • Keeps more of each sale (gross margin): 71.5% vs 65.3%
  • More profitable (operating margin): 26.2% vs 13.3%
  • Turns more of its sales into cash: 28.3% vs 15.9%
ABBV trades at 19.6x forward earnings, above the sector medianForward p/e, Biotechnology peers
REGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1xREGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 83.3x earnings, ABBV is cheaper than its average since Aug 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
100x150xAverage 95.0x2025202683.3x100x150xAverage 95.0x2025202683.3x
Source: Nasdaq prices; SEC filings

Financials

From AbbVie's SEC filings, through the quarter ending 30 Jun 2026. Hover or tap a bar for its value.

Revenue grew 10.2% from a year earlierQuarterly revenue, $bn, latest Q2 ’26
$0bn$5bn$10bn$15bnQ3 ’24Q1 ’25Q3 ’25$17.0bnQ2 ’26$0bn$10bnQ3 ’24Q1 ’25Q3 ’25$17.0bnQ2 ’26
Source: SEC filings
Growth slowed to +10.2% last quarterRevenue growth, year on year, %
0%5%10%Q3 ’24Q1 ’25Q3 ’2510.2%Q2 ’260%5%10%Q3 ’24Q1 ’25Q3 ’2510.2%Q2 ’26
Source: SEC filings
Operating margin was 37.9% last quarterOperating income as a share of revenue, %
0%20%Q3 ’24Q1 ’25Q3 ’2537.9%Q2 ’260%20%Q3 ’24Q1 ’25Q3 ’2537.9%Q2 ’26
Source: SEC filings
Free cash flow was $18.2 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $bn
$0bn$2bn$4bn$6bnQ3 ’24Q1 ’25Q3 ’25$3.1bnQ2 ’26$0bn$2bn$5bnQ3 ’24Q1 ’25Q3 ’25$3.1bnQ2 ’26
Source: SEC filings
Last 12 monthsABBVSector median
Revenue growth+10.4%+7.8%
Gross margin71.5%65.3%
Operating margin26.2%13.3%
Free cash flow margin28.3%15.9%
Price to earnings50.8x30.2x

Stories on AbbVie

Thursday, 29 October
Earnings preview

AbbVie (ABBV) Reports Earnings Tomorrow: What to Watch

AbbVie reports before the open on Friday. Analysts expect adjusted EPS of $3.74 to $3.79, within or above the $3.73 to $3.77 the company guided to after an 11-cent charge for acquired research.

ABBV▲ 1.7%
A scientist at a microscope

Similar companies

Biotechnology, by market value.

CompanyPriceTodayYTDValue
AMGNAmgen$466.01+1.15%+42.4%$252B
GILDGilead Sciences$170.68+3.06%+39.1%$212B
VRTXVertex Pharmaceuticals$558.88+3.50%+23.3%$142B
REGNRegeneron Pharmaceuticals$927.89+13.33%+20.2%$95.53B
MRNAModerna$221.72−0.47%+651.8%$88.52B
BIIBBiogen$253.62+1.59%+44.1%$37.49B
INCYIncyte$120.39+3.07%+21.9%$24.40B